5th Floor, Rajapushpa Summit
Nanakramguda Rd, Financial District, Gachibowli
Hyderabad, Telangana - 500008
The Asia Pacific Clinical Nutrition Market is segmented By Route of Administration (Oral and Enteral, Parenteral), By Application, By End-User, and Geography.
2018 - 2026
The Asia Pacific Clinical Nutrition Market is expected to register a CAGR of 7.1% during the forecast period. The major factors attributing to the growth of the Asia Pacific clinical nutrition market include an increase in the prevalence of metabolic disorders and neurological diseases, a rise in the geriatric population in the Asia Pacific Region and high spending on healthcare. For instance, Japan has the world’s fastest ageing population. According to the World Ageing 2019 report, estimates that number of population who are above 65 years of age in Japan was 35.524 million (28%) in 2019 which is projected to reach 37.278 million (30.9%) in 2030. As number of geriatric population is expected to increase in coming years who are more prone to neurological diseases such as Alzheimers diseases, Parkinsons diseases and dementia which ultimately rises the growth of market in near future.
Dietary therapy is critical for normal growth and development, to prevent acute complications, and/or to prevent long-term complications of the given disorder. A failure to follow specific dietary treatment can lead to complications and even death in individuals with metabolic disorders. Nutrition therapy for patients with inherited metabolic disorders is lifelong. The management of patients with many inborn errors of metabolism requires a multidisciplinary approach that combines both nutrition and medical management. In these disorders, nutrition therapy is a critical component of the management to prevent acute complications, such as metabolic decompensation, and/or to prevent long-term complications of the given disorder.
Most of the metabolic syndromes result in situations where the body lacks the capability to synthesize non-essential molecules, like vitamins, amino acids, and several molecules involved in metabolic pathways. Most of these conditions can be managed only with supplementation of one or two nutrients. All these factors are helping the market growth. However, there are few factors that may restrain market growth such as the heterogeneous nature of government coverage/reimbursement across countries.
As per scope of the report, clinical nutrition is an area of medicine that offers treatment of medical disorders caused due to an improper diet or due to the body’s inability to absorb the nutrients available in a normal diet. These clinical nutrition products are aimed at treating metabolic disorders, eating or nutritional disorders, and others. The Asia Pacific clinical nutrition market is segmented by route of administration, application, end-user, and geography.
|By Route of Administration|
|Oral and Enteral|
|Nutritional Support in Malnutrition|
|Nutritional Support in Metabolic Disorders|
|Nutritional Support in Gastrointestinal Diseases|
|Nutritional Support in Neurological Diseases|
|Nutritional Support in Cancer|
|Nutritional Support in Other Diseases|
|By End User|
|Rest of Asia-Pacific|
Report scope can be customized per your requirements. Click here.
Oral clinical nutrition accounts for the largest share, in terms of value, in this segment. Among all the routes of administration available for clinical nutrition, oral and enteral routes are used the most, followed by the parenteral route. This is mainly because of the additional cost of processing the product/nutrient involved in parenteral routes. Until other routes of administration are deemed necessary, physicians mostly prefer the oral route, as it involves lesser complexities and costs, compared to the other two routes of administration. As long as the patients can consume food orally, their stomach and intestine functionalities are not affected, the oral route is the preferred route of administration, for clinical nutrition.
Furthermore, according to Dementia Australia, approximately 459,000 Australians are living with dementia in 2020 and the almost 1.6 million Australians involved in their centre for care. It is also estimated that the number of people with dementia is expected to upsurge to 1.1 million by 2058. Thus, owing to the above factors along with rising geriatric population and prevalence of neurological disease such as dementia associated with Alzheimer's is expected to show growth in coming years.
To understand key trends, Download Sample Report
The Asia pacific clinical nutrition market is fragmented competitive and consists of several major players in the Asia region. In terms of market share, few of the major players are currently dominating the clinical nutrition market. And factors such as the increasing prevalence of metabolic diseases the market is expected to grow furthermore. Therefore a few other players are expected to enter into the market in the coming years. Some of the major players of the market are Abbott Nutrition, Nestle Health Science, Baxter Healthcare, B. Braun Melsungen AG, and Nutricia are among others.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Metabolic Disorders
4.2.2 Increase in Geriatric Population in Asia Pacific Region
4.2.3 High Spending on Healthcare Along with Rise of Middle-class In Emerging Economies
4.3 Market Restraints
4.3.1 Unwillingness of Hospitals and In-house Pharmacies/ Dispensaries to Maintain the Required Stock of Clinical Nutrition Products
4.3.2 Heterogeneous Nature Of Government Coverage/Reimbursement Across Countries
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Route of Administration
5.1.1 Oral and Enteral
5.2 By Application
5.2.1 Nutritional Support in Malnutrition
5.2.2 Nutritional Support in Metabolic Disorders
5.2.3 Nutritional Support in Gastrointestinal Diseases
5.2.4 Nutritional Support in Neurological Diseases
5.2.5 Nutritional Support in Cancer
5.2.6 Nutritional Support in Other Diseases
5.3 By End User
5.4.5 South Korea
5.4.6 Rest of Asia-Pacific
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Nutrition
6.1.2 Nestle Health Science
6.1.3 Baxter Healthcare
6.1.4 B. Braun Melsungen AG
6.1.6 Mead Johnson
6.1.7 Perrigo Company PLC
6.1.8 Fresenius Kabi
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments